摘要
目的:研究合并糖尿病以及胰岛素治疗对鼻咽癌患者放疗后长期生存率的影响。方法:总结86例合并糖尿病接受放疗鼻咽癌初诊患者,中位随访期50.1个月,对患者5年OS,RFS,MFS以及DFS进行分析。此外,化疗以及胰岛素治疗对远期疗效的影响也作了初步评价。结果:86例患者5年OS为47.7%,DFS为40.7%,RFS为43.0%,MFS为45.4%。接受化疗OS为48.6%,未化疗者为46.9%,统计学未显示出生存差异(P>0.05)。而同期化疗与诱导化疗相比也未显示出生存率上的优势(P>0.05)。在III,IV期患者中,接受化疗的OS为45.7%,未化疗者为23.5%,亦无统计学差异(P>0.05)。27例(31.4%)接受胰岛素治疗的患者中,5年OS,RFS,MFS分别为33.3%,33.3%,33.3%;未注射胰岛素的患者则为54.2%,47.5%,50.8%(P<0.05)。37例接受化疗的患者中,同时注射胰岛素患者的OS为28.6%而未注射的患者为60.9%(P<0.05)。结论:化疗对合并糖尿病的鼻咽癌患者生存时间的延长作用不明显,而接受胰岛素治疗似乎对这类患者的远期生存有不利影响。
Objective： To investigate the influence of diabetes mellitus and insulin therapy on treatment outcomes in patients with nasopharyngeal cancer.Methods： We summarized 86 patients diagnosed as having diabetes and nasopharyngeal cancer,treated by radiotherapy between January 1999 and December 2002,with a median follow-up of 50.1 months.We analyzed the OS,RFS,MFS and DFS.Furthermore,the affect of chemotherapy and insulin therapy on long-term outcomes were investigated.Results： The OS of 86 patients was 47.7%,DFS 40.7%,RFS 43.0% and MFS45.4%.OS of chemotherapy group was 48.6% vs 46.9% of non-chemotherapy group（P〉0.05）.There was no significant difference between induction and concurrent chemotherapy groups（P〉0.05）.For patients diagnosed as advanced stage,OS of chemotherapy group was 45.7% vs 23.5% in non-chemotherapy group（P〉0.05）.27（31.4%） patients received insulin therapy,OS,RFS,MFS of insulin group was 33.3%,33.3%,33.3% vs 54.2%,47.5%,50.8% in non-insulin group（P〈0.05）.Among 37 patients received chemotherapy,14 had insulin therapy.OS of insulin group was 28.6% vs 60.9% of non-insulin group in chemotherapy patients（P〈0.05）.Conclusion： hemotherapy didn＇t have advantages in nasopharyngeal cancer patients with diabetes.Insulin therapy had adverse affect on long-term survival in nasopharyngeal cancer patients.
出处
《赣南医学院学报》
2009年第6期887-888,984,共3页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
关键词
鼻咽癌
糖尿病
放射治疗
化疗
胰岛素
Nasopharyngeal cancer
Diabetes
Radiotherapy
Chemotherapy
Insulin
